{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:22:58Z","timestamp":1761016978946},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,9,29]],"date-time":"2012-09-29T00:00:00Z","timestamp":1348876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s40263-012-0007-0","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T20:09:43Z","timestamp":1355774983000},"page":"983-991","source":"Crossref","is-referenced-by-count":5,"title":["Clobazam"],"prefix":"10.1007","volume":"26","author":[{"given":"Lily P. H.","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,29]]},"reference":[{"issue":"Suppl 1","key":"7_CR1","first-page":"S3","volume":"13","author":"A Arzimanoglou","year":"2011","unstructured":"Arzimanoglou A, Resnick T. All children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome \u2026 but many do. Epileptic Disord. 2011;13(Suppl 1):S3\u201313.","journal-title":"Epileptic Disord"},{"issue":"1","key":"7_CR2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","volume":"8","author":"A Arzimanoglou","year":"2009","unstructured":"Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82\u201393.","journal-title":"Lancet Neurol"},{"issue":"6","key":"7_CR3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/NDT.S1668","volume":"4","author":"K Rijckevorsel van","year":"2008","unstructured":"van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatri Dis Treat. 2008;4(6):1001\u201319.","journal-title":"Neuropsychiatri Dis Treat"},{"issue":"6","key":"7_CR4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00002018-200022060-00005","volume":"22","author":"D Schmidt","year":"2000","unstructured":"Schmidt D, Bourgeois B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf. 2000;22(6):467\u201377.","journal-title":"Drug Saf"},{"key":"7_CR5","doi-asserted-by":"crossref","unstructured":"Hancock EC, Cross HJ. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2009; (4): CD003277.","DOI":"10.1002\/14651858.CD003277.pub2"},{"issue":"Suppl 5","key":"7_CR6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2011.03178.x","volume":"52","author":"GD Montouris","year":"2011","unstructured":"Montouris GD. Rational approach to treatment options for Lennox-Gastaut syndrome. Epilepsia. 2011;52(Suppl 5):10\u201320.","journal-title":"Epilepsia"},{"issue":"2","key":"7_CR7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/11536940-000000000-00000","volume":"13","author":"PK Crumrine","year":"2011","unstructured":"Crumrine PK. Management of seizures in Lennox-Gastaut syndrome. Paediatr Drugs. 2011;13(2):107\u201318.","journal-title":"Paediatr Drugs"},{"issue":"8","key":"7_CR8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2009.06.005","volume":"18","author":"K Gallop","year":"2009","unstructured":"Gallop K, Wild D, Nixon A, et al. Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 2009;18(8):554\u20138.","journal-title":"Seizure"},{"issue":"2","key":"7_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","volume":"118","author":"J Riss","year":"2008","unstructured":"Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118(2):69\u201386.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"7_CR10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","volume":"26","author":"R Sankar","year":"2012","unstructured":"Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26(3):229\u201344.","journal-title":"CNS Drugs"},{"key":"7_CR11","unstructured":"National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (NICE clinical guideline 137). http:\/\/www.nice.org.uk\/nicemedia\/live\/13635\/57779\/57779.pdf . Accessed 24 Jul 2012."},{"key":"7_CR12","unstructured":"Sanofi Aventis. Frisium\u2122 (clobazam) 10\u00a0mg tablets: summary of product characteristics. http:\/\/www.medicines.org.uk\/EMC\/medicine\/8298\/SPC\/Frisium+Tablets+10+mg\/ . Accessed 23 Jul 2012."},{"issue":"1","key":"7_CR13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","volume":"4","author":"Y-T Ng","year":"2007","unstructured":"Ng Y-T, Collins SD. Clobazam. Neurotherapeutics. 2007;4(1):138\u201344.","journal-title":"Neurotherapeutics"},{"key":"7_CR14","unstructured":"Lunbeck Inc. Onfi\u2122 (clobazam) oral tablets: US prescribing information. http:\/\/www.lundbeck.com\/upload\/us\/files\/pdf\/Products\/Onfi_PI_US_EN.pdf . Accessed 2 Aug 2012."},{"key":"7_CR15","doi-asserted-by":"crossref","unstructured":"Jensen HS, Ebert B. Clobazam and its active metabolite, N-desmethylclobazam, are high-affinity ligands for the benzodiazepine sites of GABAA receptors [abstract no. P05.086]. Neurology. 2012;78 Suppl 1.","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P05.086"},{"issue":"8","key":"7_CR16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","volume":"47","author":"W L\u00f6scher","year":"2006","unstructured":"L\u00f6scher W, Schmidt D. Experimental and clinical evidence of loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47(8):1253\u201384.","journal-title":"Epilepsia"},{"issue":"9","key":"7_CR17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1528-1157.1998.tb01444.x","volume":"39","author":"Canadian Study Group for Childhood Epilepsy","year":"1998","unstructured":"Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia. 1998;39(9):952\u20139.","journal-title":"Epilepsia"},{"key":"7_CR18","doi-asserted-by":"crossref","unstructured":"Hussein Z, Ferry J, Krauss G, et al. Demographic factors and concomitant antiepileptic drugs have no effect on the pharmacodynamics of perampanel [abstract no. P06.127]. Neurology. 2012;78 Suppl 1.","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.127"},{"issue":"1","key":"7_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11596290-000000000-00000","volume":"26","author":"A Falc\u00e3o","year":"2012","unstructured":"Falc\u00e3o A, Fuseau E, Nunes T, et al. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses. CNS Drugs. 2012;26(1):79\u201391.","journal-title":"CNS Drugs"},{"issue":"4","key":"7_CR20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","volume":"32","author":"M Walzer","year":"2012","unstructured":"Walzer M, Bekersky I, Blum RA, et al. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340\u201353.","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"7_CR21","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1111\/j.1365-2125.1979.tb04664.x","volume":"7","author":"M Volz","year":"1979","unstructured":"Volz M, Christ O, Kellner HM, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol. 1979;7(Suppl 1):41S\u201350S.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"7_CR22","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1111\/j.1365-2125.1979.tb04665.x","volume":"7","author":"W Rupp","year":"1979","unstructured":"Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol. 1979;7(Suppl 1):51S\u20137S.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"7_CR23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32(11):1279\u201386.","journal-title":"Drug Metab Dispos"},{"key":"7_CR24","doi-asserted-by":"crossref","unstructured":"Renfroe J, Conry J, Ng Y-T, et al. Effects of concomitant lamotrigine or valproate therapy on clobazam for Lennox-Gastaut syndrome: subanalyses of the CONTAIN trial [abstract no. P06.120]. Neurology 2012;78 Suppl 1.","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.120"},{"key":"7_CR25","doi-asserted-by":"crossref","unstructured":"Mitchell W, Conry J, Ng Y-T, et al. Clobazam is efficacious for drop attacks in patients with Lennox-Gastaut syndrome across the age spectrum: subgroup analysis of the CONTAIN trial [abstract no. P06.096]. Neurology 2012;78 Suppl 1.","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.096"},{"key":"7_CR26","doi-asserted-by":"crossref","unstructured":"Ng Y-T, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77 (15): 1473\u201381. http:\/\/www.neurology.com . Accessed 24 Jul 2012.","DOI":"10.1212\/WNL.0b013e318232de76"},{"issue":"5","key":"7_CR27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","volume":"50","author":"JA Conry","year":"2009","unstructured":"Conry JA, Ng Y-T, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50(5):1158\u201366.","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"7_CR28","first-page":"S15","volume":"70","author":"Y-T Ng","year":"2011","unstructured":"Ng Y-T, Conry JA, Paolicchi JM, et al. Long-term safety and efficacy of clobazam for Lennox Gastaut syndrome (LGS): 2-year results of an open label extension (OLE) study [abstract no. 14]. Ann Neurol. 2011;70(Suppl 1):S15\u2013140.","journal-title":"Ann Neurol"},{"key":"7_CR29","doi-asserted-by":"crossref","unstructured":"Tolbert D, Harris S, Bekersky I, et al. Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome (LGS) [abstract no. P06.106]. Neurology 2012; 78 (Suppl 1).","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.106"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0007-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-012-0007-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0007-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T22:05:53Z","timestamp":1595109953000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-012-0007-0"}},"subtitle":["In Patients with Lennox\u2013Gastaut Syndrome"],"short-title":[],"issued":{"date-parts":[[2012,9,29]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1007\/s40263-012-0007-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,29]]}}}